This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HECKMAN, J. D.
Right arrow Articles by BOYAN, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HECKMAN, J. D.
Right arrow Articles by BOYAN, B. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?
The Journal of Bone and Joint Surgery 81:1717-29 (1999)
© 1999 The Journal of Bone and Joint Surgery, Inc.

Bone Morphogenetic Protein But Not Transforming Growth Factor-ß Enchances Bone Formation in Canine Diaphyseal Nonunions Implanted with a Biodegradable Composite Polymer*{dagger}

JAMES D. HECKMAN, M.D.{ddagger}, SAN ANTONIO, WILLIAM EHLER, D.V.M.§, LACKLAND AIR FORCE BASE, BRYAN P. BROOKS, B.A.#, THOMAS B. AUFDEMORTE, D.D.S.#, CHRISTOPH H. LOHMANN, M.D.#, THANE MORGAN, M.D.# and BARBARA D. BOYAN, PH.D.#, SAN ANTONIO, TEXAS

Investigation performed at the Departments of Orthopaedics and Pathology, The University of Texas Health Science Center at San Antonio, San Antonio; the Audie L. Murphy Memorial Veterans Administration Hospital, San Antonio; and Wilford Hall Medical Center, Lackland Air Force Base

Background: The purpose of the present study was to create an effective bone-graft substitute for the treatment of a diaphyseal nonunion. Methods: A standardized nonunion was established in the midportion of the radial diaphysis in thirty mongrel dogs by creating a three-millimeter segmental bone defect (at least 2 percent of the total length of the bone). The nonunion was treated with implantation of a carrier comprised of poly(DL-lactic acid) and polyglycolic acid copolymer (50:50 polylactic acid-polyglycolic acid [PLG50]) containing canine purified bone morphogenetic protein (BMP) or recombinant human transforming growth factor-ß (TGF-ß1), or both, or the carrier without BMP or TGF-ß1. Five groups, consisting of six dogs each, were treated with implantation of the carrier alone, implantation of the carrier with fifteen milligrams of BMP, implantation of the carrier with 1.5 milligrams of BMP, implantation of the carrier with fifteen milligrams of BMP and ten nanograms of TGF-ß1, or implantation of the carrier with ten nanograms of TGF-ß1. At twelve weeks after implantation, the radii were examined radiographically and the sites of nonunion were examined histomorphometrically. Results: We found that implantation of the polylactic acid-polyglycolic acid carrier alone or in combination with ten nanograms of TGF-ß1 failed to induce significant radiographic or histomorphometric evidence of healing at the site of the nonunion. The radii treated with the carrier enriched with either 1.5 or fifteen milligrams of BMP showed significantly increased periosteal and endosteal bone formation on histomorphometric (p < 0.05) and radiographic (p < 0.02) analysis. Conclusions: Bone formation in a persistent osseous defect that is similar to an ununited diaphyseal fracture is increased when species-specific BMP incorporated into a polylactic acid-polyglycolic acid carrier is implanted at the site of the nonunion. TGF-ß1 at a dose of ten nanograms per implant did not induce a similar degree of bone formation or potentiate the effect of BMP in this model. Clinical Relevance: The biodegradable implant containing BMP that was used in the present study to treat diaphyseal nonunion is an effective bone-graft substitute.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul
Transforming Growth Factor-{beta}1 to the Bone
Endocr. Rev., October 1, 2005; 26(6): 743 - 774.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
D. M. Ranly, J. McMillan, T. Keller, C. H. Lohmann, T. Meunch, D. L. Cochran, Z. Schwartz, and B. D. Boyan
Platelet-Derived Growth Factor Inhibits Demineralized Bone Matrix-Induced Intramuscular Cartilage and Bone Formation. A Study of Immunocompromised Mice
J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2052 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
M.F. Termaat, F.C. Den Boer, F.C. Bakker, P. Patka, and H.J.Th.M. Haarman
Bone Morphogenetic Proteins. Development and Clinical Efficacy in the Treatment of Fractures and Bone Defects
J. Bone Joint Surg. Am., June 1, 2005; 87(6): 1367 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
H. Seeherman, R. Li, and J. Wozney
A Review of Preclinical Program Development for Evaluating Injectable Carriers for Osteogenic Factors
J. Bone Joint Surg. Am., August 1, 2003; 85(90003): 96 - 108.
[Full Text] [PDF]